Sign Up for Free!

Continue Analyzing the page and more.

Already have an Account? Log In

The Trial has ended

Continue Analyzing the page and more.

Bio-Techne Corp logo
TECH

Bio-Techne Corp

MaveScore 42 Low model confidence
Last Price US$56.50 As of Jun 15, 2026
Market Cap US$7.5b Company size context
7D Performance 6.10% Past 7 days
1Y Performance 14.14% Past 12 months
Model Rating
Historical model output for research review

Fundamental data date

Mar 31, 2026

77 days old

Market price date

Jun 15, 2026

1 day old

Coverage

16/16

No missing model inputs

Data quality

Excellent

Current stored snapshot

Transparent research score

Why the model scores this stock

MaveScore is a research prioritization score from 0 to 100. It is historical model output for watchlist review, not personalized financial advice.

MaveScore 42 Low confidence

Stored data quality

Freshness and coverage checks

Latest stored fundamentals and price inputs are recent enough for normal research review.

16/16 Current stored snapshot

Quality

Quality score blends the latest weighted model rank with underlying profitability and dilution ranks.

22/35 Mixed

Financial Strength

Financial strength rewards durable profitability, margins, and positive free cash flow.

11/25 Weak

Valuation Support

Valuation favors positive earnings, positive cash flow, and lower price-to-book multiples.

2/15 Weak

Momentum

Momentum highlights research candidates with supportive 3-month and 6-month price regimes.

6/15 Weak

Shareholder Alignment

Shareholder alignment rewards less dilutive share behavior and enough size for liquid research coverage.

1/10 Weak

Positive model output

More live company inputs are needed before positive research signals can be surfaced.

Research risks to review

  • Financial strength rewards durable profitability, margins, and positive free cash flow.
  • Valuation favors positive earnings, positive cash flow, and lower price-to-book multiples.
  • Momentum highlights research candidates with supportive 3-month and 6-month price regimes.

MaveScore uses historical model inputs, stored company fundamentals, and stored price context for research support only. Review missing inputs and business-specific risks before acting.

Dashboard Funda..tals Deep..lue Prediction Screener Map

Bio-Techne Corp Overview

Industry: Biotechnology

Sector: Healthcare

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. It has strategic partnership with Lunaphore Technologies S.A. to develop automated same-slide spatial multiomics solution. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.

Bio-Techne Corp is evaluated using Mavefund's quality framework: growing earnings, durable profit margins, conservative leverage, strong return on equity, and disciplined share repurchases.

Score

Price History & Performance

Review Bio-Techne Corp in context before unlocking the interactive price chart, financial overlays, and downloadable ratio tables.

Recent News



Bio-Techne Corp Competitors

Bio-Techne Corp operates in the Biotechnology industry within the Healthcare sector. Unlock the full page to compare peer rankings, valuation quality, profitability, leverage, and growth trends.

Earnings Per Share

EPS quality is one of the core Mavefund signals. Sign up to continue into the detailed EPS, ROE, margin, share buyback, leverage, and financial ratio analysis.

Continue the analysis

Sign up to unlock ROE, net margin, share buyback, leverage, financial ratios, peer charts, and downloads.

View plans
Ticker Image

Bio-Techne Corp

US$56.50

US$7.5b

6.10%

14.14%